Anterix Inc.

Fundamentals3.0
Price Action6.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Profitability Squeeze
  • Liquidity Deterioration
  • Intangible Overhang

AI
AI Summary

5.0

ATEX has shifted from a high-risk explorer to a more credible copper-gold story after the Chile suspension was lifted, cash was boosted by a $52.5M warrant exercise, and a TSX uplisting is near, but with cash still declining, losses widening, and the stock already overbought, the current re-rating depends on Valeriano drilling quickly proving durable economic value or it could reverse.

CopperGold
ExecutionRisk
Overbought‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

3.0

Key Financial Insights:

  • Profitability Squeeze
  • Liquidity Deterioration
  • Intangible Overhang

ATEX remains fundamentally weak, with continued losses, poor returns and thinning liquidity despite modest debt, while heavy intangible assets and a >89x price-to-sales multiple leave the stock looking expensive and high risk.

losses
overvalued

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Strong breakout
  • Fresh high
  • Extended momentum

ATEX is in a strong last month uptrend and just hit a fresh high, but RSI near 74 suggests it is extended and may pause or pull back near $57.

uptrend
overbought
Support Level: $55.29-$55.72
Resistance Level: $57.06

Decisive breakout from about $48.38 to above $55, with the $54.25 dip looking like a brief pause

Sentiment & News

6.0

Key News Insights:

  • Regulatory clearance
  • TSX uplist
  • Network expansion

ATEX Resources regained regulatory clearance and advanced toward a TSX uplist with board refresh, while Anterix secured a private 900 MHz network deal and drew continued interest amid valuation scrutiny.

ATEX

The headlines are constructive for ATEX Resources' operational recovery and listing profile, while Anterix's commercialization progress supports the story but valuation concerns may cap near-term upside